AU Patent

AU2020259461A1 — CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo

Assigned to Allergan Sales LLC · Expires 2021-11-11 · 5y expired

What this patent protects

The application provides methods for treating, preventing, alleviating or reducing the frequency of occurrence of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo in patients by the administration of calcitonin gene-related peptide (CGRP-…

USPTO Abstract

The application provides methods for treating, preventing, alleviating or reducing the frequency of occurrence of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo in patients by the administration of calcitonin gene-related peptide (CGRP-antagonists). The CGRP-antagonists can be selected from ubrogepant or atogepant, or a pharmaceutically acceptable salt, ester or prodrug thereof. Anti-CGRP antibodies, such galcanezumab, fremanezumab, eptinezumab, and erenumab can also be used.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020259461A1
Jurisdiction
AU
Classification
—
Expires
2021-11-11
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Sales LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.